Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: A 6-year follow-up study

Review of Diabetic Studies

Volumn 7, Issue 3, 2010, Pages 231-238

  Alvarsson, Michael ^a   Berntorp, Kerstin ^b   Fernqvist Forbes, Eva ^c   Lager, Ibe ^d   Steen, Lars ^e   Örn, Thomas ^f   Grill, Valdemar ^a,g  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Department of Medical Sciences   (Sweden)

^d CENTRAL HOSPITAL   (Sweden)

^e Mälarsjukhuset Hospital   (Sweden)

^f BLEKINGE HOSPITAL   (Sweden)

^g TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Beta cell function; Insulin secretion; Islet amyloid polypeptide; Sulphonylurea; Type 2 diabetes

Indexed keywords

AMYLIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLUCAGON; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ISOPHANE INSULIN; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETIC PATIENT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; METABOLISM; MIDDLE AGED; SECRETION;

ADULT; AGED; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLUCAGON; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED;

EID: 79551695874     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2010.7.231     Document Type: Article

References (17)

1. Grill V, Björklund A. Overstimulation and beta-cell function. Diabetes 2001. 50(Suppl 1):S122-S124.
2. Buchanan TA. Pancreatic beta-cell loss and preservation in type 2 diabetes. Clin Ther 2003. 25(Suppl B):B32-B46.
3. Fridlyand LE, Philipson LH. Does the glucose-dependent insulin secretion mechanism itself cause oxidative stress in pancreatic beta-cells? Diabetes 2004. 53:1942-1948.
4. Donath MY, Schumann DM, Faulenbach M, Ellingsgard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 2008. 31(Suppl 2):S161-S164.
5. DeFronzo RA. From the triumvirate to ominous octet: a new paradigm for the treatment of type 2 diabetes. Diabetes 2009. 58:773-795.
6. Ritzel RA, Meier JJ, Lin CY, Veldhuis JD, Butler PC. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes 2007. 56:65-71.
7. Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E, Steen L, Westermark G, Westermark P, Örn T, et al. Beneficial effects of insulin versus sulphoylurea on insulin secretion and metabolic control in recently diagnosed type diabetic patients. Diabetes Care 2003. 26:2231-2237.
8. Alvarsson M, Sundkvist G, Lager I, Berntorp K, Fernqvist-Forbes E, Steen L, Örn T, Holberg MA, Kirksaether M, Grill V. Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. Diabetes Obes Metab 2008. 10:421-429.
9. Jeppsson JO, Jerntorp P, Almer LO, Persson R, Ekberg G, Sundkvist G. Capillary blood on filter paper for determination of HbA1c by ion exchange chromatography. Diabetes Care 1996. 19:142-145.
10. Henricsson M, Nyström L, Blohme G, Östman J, Kullberg C, Svensson M, Schölin A, Arnqvist HJ, Björk E, Bolinder J, et al. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 2003. 26:349-354. (Pubitemid 36929054)
11. Borg H, Fernlund P, Sundkvist G. Protein tyrosine phosphatase-like protein IA2-antibodies plus glutamic acid decarboxylase 65 antibodies (GADA) indicates autoimmunity as frequently as islet cell antibodies assay in children with recently diagnosed diabetes mellitus. Clin Chem 1997. 43:2358-2363.
12. Borg H, Fernlund P, Sundkvist G. Measurement of antibodies against glutamic acid decarboxylase 65 (GADA): two new 125I assays compared with 35S GAD 65-ligand binding assay. Clin Chem 1997. 43(5):779-785.
13. Jeppsson JO, Jerntorp P, Sundkvist G, Englund H, Nylund V. Measurement of hemoglobin A1c by a new liquid-chromatographic assay: methodology, clinical utility, and relation to glucose tolerance evaluated. Clin Chem 1986. 32:1867-1872.
14. Rachman J, Payne MJ, Levy JC, Barrow BA, Holman RR, Turner RC. Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM. Diabetes Care 1998. 21:810-816.
15. Groop L, Schalin C, Franssila-Kallunki A, Widen E, Ekstrand A, Eriksson J. Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy. Am J Med 1989. 87:183-190.
16. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999. 131:281-303.
17. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002. 346:393-403.